Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | LGMN | Q99538 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | HPD | P32754 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6678209 | 0.85 | ALDH1A1 (0.38) | GAAL3MBTL1ALDH1A1LMNACYP3A4 | |
| SCHEMBL6789030 | 0.82 | L3MBTL1 (0.42) | GAAL3MBTL1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6679197 | 0.82 | ALDH1A1 (0.49) | L3MBTL1ALDH1A1LMNASMN1; SMN2CYP3A4 | |
| SCHEMBL6678368 | 0.80 | MEN1 (0.41) | GAAL3MBTL1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6684431 | 0.79 | KMT2A (0.49) | ALDH1A1LMNASMN1; SMN2PKMCYP3A4 | |
| SCHEMBL6678512 | 0.77 | SMN1; SMN2 (0.45) | GAAALDH1A1LMNASMN1; SMN2PKM | |
| SCHEMBL7061898 | 0.76 | GAA (0.47) | GAAL3MBTL1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL7059744 | 0.74 | GAA (0.43) | GAAL3MBTL1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6789742 | 0.71 | LMNA (0.40) | GAAALDH1A1LMNASMN1; SMN2PKM | |
| SCHEMBL6788504 | 0.71 | ALDH1A1 (0.39) | ALDH1A1LMNASMN1; SMN2PKMCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224951-A1 | 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | ROARK WILLIAM HOWARD (US) | 2004-11-11 | — | — | US | disclosed |
| WO-2004014921-A1 | 5,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224951-A1 | 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | MMP9, MMP13, MMP25 | GAA 358/4885L3MBTL1 2277/4885ALDH1A1 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.